Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Luc Bonneux, associate professor (l.bonneux@jc.azu.nl)
  1. Julius Center for Health Sciences, Utrecht Medical Center, HP D 01.335, PO Box 85500NL-3508 GA Utrecht, Netherlands

    EDITOR—In their key points Lu-Yao et al say that the lack of association between more intensive screening and treatment and lower mortality from prostate cancer means that trials should continue to settle this question.1 More research is the classic conclusion of all studies, but is it true?

    Firstly, trials cannot be used to prove that something does not work. That is unethical; there has to …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular